share_log

藥明生物：高級管理人員退任及董事調任

WUXI BIO: RETIREMENT OF SENIOR MANAGEMENT AND RE-DESIGNATION OF DIRECTOR

香港交易所 ·  Apr 1 19:11
Summary by Futu AI
药明生物技术有限公司宣布，周博士自2024年3月31日起退任公司首席技术官及全球生物製藥開發及運營總裁職務，並調任為非執行董事及全球生物製藥開發及運營名譽總裁及首席執行官高級顧問。周博士將繼續留任董事會戰略委員會成員，支援公司發展。周博士在生物製劑開發及生產領域擁有豐富經驗，曾於多家國際生物製藥公司擔任高級職位。新任期為期三年，周博士將收取年薪1,200,000港元。此外，周博士在公司擁有股份及多項股權。董事會對周博士的調任表示肯定，並無需股東及聯交所另行關注。
药明生物技术有限公司宣布，周博士自2024年3月31日起退任公司首席技术官及全球生物製藥開發及運營總裁職務，並調任為非執行董事及全球生物製藥開發及運營名譽總裁及首席執行官高級顧問。周博士將繼續留任董事會戰略委員會成員，支援公司發展。周博士在生物製劑開發及生產領域擁有豐富經驗，曾於多家國際生物製藥公司擔任高級職位。新任期為期三年，周博士將收取年薪1,200,000港元。此外，周博士在公司擁有股份及多項股權。董事會對周博士的調任表示肯定，並無需股東及聯交所另行關注。
PHARMA MING BIOTECHNOLOGY CO., LTD. ANNOUNCED THAT DR. ZHOU WILL RETIRE AS CHIEF TECHNOLOGY OFFICER AND PRESIDENT OF GLOBAL BIOPHARMACEUTICAL DEVELOPMENT AND OPERATIONS EFFECTIVE MARCH 31, 2024, AND HAS BEEN APPOINTED AS A NON-EXECUTIVE DIRECTOR AND HONORARY PRESIDENT OF GLOBAL BIOPHARMACEUTICAL DEVELOPMENT AND OPERATIONS AND SENIOR ADVISOR TO THE CHIEF EXECUTIVE OFFICER. Dr. Zhou will continue to serve as a member of the Board's Strategic Committee to support the company's development. Dr. Zhou has extensive experience in the field of biopharmaceutical development and production and has held senior positions in several international biopharmaceutical companies. Dr Zhou will receive an annual salary of HK$1,200,000 for a new term of three years. In addition, Dr. Zhou owns shares and several equity interests in the company. The Board of Directors is satisfied with the appointment of Dr. Zhou that there is no need for the shareholders and the exchange to be taken into account separately.
PHARMA MING BIOTECHNOLOGY CO., LTD. ANNOUNCED THAT DR. ZHOU WILL RETIRE AS CHIEF TECHNOLOGY OFFICER AND PRESIDENT OF GLOBAL BIOPHARMACEUTICAL DEVELOPMENT AND OPERATIONS EFFECTIVE MARCH 31, 2024, AND HAS BEEN APPOINTED AS A NON-EXECUTIVE DIRECTOR AND HONORARY PRESIDENT OF GLOBAL BIOPHARMACEUTICAL DEVELOPMENT AND OPERATIONS AND SENIOR ADVISOR TO THE CHIEF EXECUTIVE OFFICER. Dr. Zhou will continue to serve as a member of the Board's Strategic Committee to support the company's development. Dr. Zhou has extensive experience in the field of biopharmaceutical development and production and has held senior positions in several international biopharmaceutical companies. Dr Zhou will receive an annual salary of HK$1,200,000 for a new term of three years. In addition, Dr. Zhou owns shares and several equity interests in the company. The Board of Directors is satisfied with the appointment of Dr. Zhou that there is no need for the shareholders and the exchange to be taken into account separately.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.